Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Motzer

Showing results (61-70 of 436) with videos related to

Pageof 44
Sort By:
Health and Quality of Life Outcomes|September 28, 2006
A brief symptom index for advanced renal cell carcinomaDavid T Eton, David Cella, Jennifer Bacik, et al.
The Oncologist|November 4, 2016
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell CarcinomaRobert J Motzer, Bernard Escudier, Andrew Gannon, et al.
Nature Reviews. Urology|July 31, 2025
Biomarkers for renal cell carcinoma - a pragmatic approachZiad Bakouny, A Ari Hakimi, Ed Reznik, et al.
Clinical Pharmacokinetics|May 8, 2016
Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal TumorReza Khosravan, Robert J Motzer, Elena Fumagalli, et al.
BJU International|April 29, 2006
Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survivalJ James Bruno, Mark E Snyder, Robert J Motzer, et al.
Expert Opinion on Investigational Drugs|April 26, 2006
Sunitinib malate for the treatment of solid tumours: a review of current clinical dataRobert J Motzer, Sakina Hoosen, Carlo L Bello, et al.
JAMA|February 14, 2008
Medical treatment of advanced testicular cancerDarren R Feldman, George J Bosl, Joel Sheinfeld, et al.
Clinical Genitourinary Cancer|February 14, 2009
Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinomaPremal H Patel, Peggy L Senico, Rafael E Curiel, et al.
Hematology/Oncology Clinics of North America|May 17, 2011
A review of second-line chemotherapy and prognostic models for disseminated germ cell tumorsMartin H Voss, Darren R Feldman, George J Bosl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinomaEdit Remák, Claudie Charbonneau, Sylvie Négrier, et al.
Pageof 44

Showing results (61-70 of 436) with videos related to

Sort By:
Pageof 44
Health and Quality of Life Outcomes|September 28, 2006
A brief symptom index for advanced renal cell carcinomaDavid T Eton, David Cella, Jennifer Bacik, et al.
The Oncologist|November 4, 2016
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell CarcinomaRobert J Motzer, Bernard Escudier, Andrew Gannon, et al.
Nature Reviews. Urology|July 31, 2025
Biomarkers for renal cell carcinoma - a pragmatic approachZiad Bakouny, A Ari Hakimi, Ed Reznik, et al.
Clinical Pharmacokinetics|May 8, 2016
Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal TumorReza Khosravan, Robert J Motzer, Elena Fumagalli, et al.
BJU International|April 29, 2006
Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survivalJ James Bruno, Mark E Snyder, Robert J Motzer, et al.
Expert Opinion on Investigational Drugs|April 26, 2006
Sunitinib malate for the treatment of solid tumours: a review of current clinical dataRobert J Motzer, Sakina Hoosen, Carlo L Bello, et al.
JAMA|February 14, 2008
Medical treatment of advanced testicular cancerDarren R Feldman, George J Bosl, Joel Sheinfeld, et al.
Clinical Genitourinary Cancer|February 14, 2009
Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinomaPremal H Patel, Peggy L Senico, Rafael E Curiel, et al.
Hematology/Oncology Clinics of North America|May 17, 2011
A review of second-line chemotherapy and prognostic models for disseminated germ cell tumorsMartin H Voss, Darren R Feldman, George J Bosl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinomaEdit Remák, Claudie Charbonneau, Sylvie Négrier, et al.
Pageof 44